TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08
during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled
with current therapy.